RPG Life Sciences Q4 FY26: stock jumps 14%, ₹24 dividend

Stock rallies in a weak market

Shares of RPG Life Sciences attracted strong buying interest on Thursday, April 30, after the company announced its financial results for the fourth quarter and the full year ended March 31, 2026. The move stood out because the broader market was weak during the session. Investor sentiment was also supported by the company’s dividend announcement for FY26. Following the updates, the stock surged as much as 13.88% to an intraday high of ₹2,312.4 per share on the NSE. The rally came despite a sharp year-on-year fall in quarterly profit.

How the price action played out on April 30

The stock remained in demand even after partially paring intraday gains. At 02:23 PM, RPG Life Sciences was trading at ₹2,250 per share, up 10.81% from its previous close of ₹2,030.50 on the NSE. In contrast, the NSE Nifty 50 was down 174 points, or 0.72%, at 24,003. The sharp relative outperformance reflected investor focus on revenue growth and the cash return signal from the dividend.

Q4 FY26 results: revenue up, profit down

RPG Life Sciences reported revenue from operations of ₹176.89 crore in Q4 FY26. This was up 23.61% year-on-year from ₹143.09 crore in Q4 FY25. On a sequential basis, revenue slipped 1.74% from ₹180.03 crore in Q3 FY26.

Profit after tax (PAT) for the quarter stood at ₹30 crore, down 74.42% year-on-year from ₹117.35 crore in Q4 FY25. However, PAT rose 35.54% sequentially from ₹22.13 crore in Q3 FY26. The numbers show a quarter where operating momentum in sales was positive, but reported profitability was heavily influenced by the prior year’s base.

Expenses rose in line with growth

Total expenses during the quarter rose 21.92% year-on-year to ₹150.15 crore from ₹123.15 crore in Q4 FY25. Sequentially, expenses increased 2.92% from ₹145.90 crore in Q3 FY26. With revenue broadly flat quarter-on-quarter and costs higher, the quarter also reflected pressure from higher spending relative to Q3.

The key swing factor: exceptional gains

The year-on-year profit comparison in Q4 was distorted by exceptional items. The report cited exceptional gains of ₹1.1 crore in Q4 FY26 versus gains of ₹109.9 crore in Q4 FY25. This large difference helps explain why PAT fell sharply even as revenue grew strongly.

Separately, the article context noted that in the March 2025 quarter the company recorded a profit that reflected assignment of surplus vacant leasehold land along with built-up structures at MIDC, Navi Mumbai, contributing to a net exceptional gain of ₹109.90 crore in Q4 FY25. Against that base, Q4 FY26 profit trends look weaker on a reported basis.

Dividend recommendation: ₹24 per share for FY26

Along with the results, the company said its board of directors has recommended a dividend of ₹24 per equity share. This translates to 300% on the face value of ₹8 per share, fully paid up, for FY26. The dividend is subject to shareholders’ approval at the ensuing Annual General Meeting (AGM).

The company said the dividend will be paid or dispatched within 30 days of such approval. It has set June 19, 2026, as the record date for determining entitlement, if the dividend is declared at the AGM. These timelines matter for investors tracking eligibility and expected payout windows.

Where the stock stands versus key reference points

The rally added to a rebound from recent lows. The stock has risen 33.43% from its 52-week low of ₹1,733 per share, touched on March 23, 2026, on the NSE. On the day of results, the intraday high of ₹2,312.4 put the stock firmly above the previous close of ₹2,030.50.

The report also noted a seasonality datapoint: 13 out of 18 years, RPG Life Sciences has given positive returns in April. While not a forecast, it provides historical context for investor interest during the month.

Key numbers at a glance

Price and event timeline

Market impact: what investors were reacting to

The market reaction combined two forces visible in the numbers. First, the top line in Q4 grew 23.61% year-on-year, a pace that typically draws attention in a quarter where the headline profit number is volatile. Second, the dividend announcement gave investors a clear, quantified shareholder return signal at ₹24 per share, with a stated record date.

At the same time, the scale of the year-on-year PAT decline also reflects how exceptional items can reshape quarterly comparisons. With exceptional gains much lower in Q4 FY26 than the prior year’s quarter, reported profit did not mirror the revenue growth. The share move suggests investors looked past the one-time base effect and focused on the broader operating picture and the confirmed dividend process.

What to watch next

The dividend will be final only after shareholders vote at the ensuing AGM, and the company has stated it will pay or dispatch the dividend within 30 days of approval. The record date is June 19, 2026, which will determine entitlement if the dividend is declared.

The company also scheduled its Q4 FY26 earnings call for April 30, 2026, at 3:30 PM IST, hosted virtually with Managing Director Mr. Ashok Nair and CFO Mr. Amol Lone. Investors will track the call for additional colour on quarterly performance, cost trends, and the FY26 outcome.

Conclusion

RPG Life Sciences’ stock jump on April 30 reflected a combination of strong Q4 revenue growth and a ₹24-per-share dividend recommendation, even as reported quarterly profit fell sharply due to a much lower exceptional gain base. The next confirmed milestones are the June 19, 2026 record date and the shareholder vote at the upcoming AGM, after which the company has said the dividend will be paid within 30 days of approval.